The estimated Net Worth of Nadir Mahmood is at least $1.33 Миллион dollars as of 20 June 2023. Dr Mahmood owns over 526 units of Nkarta stock worth over $550,682 and over the last 4 years he sold NKTX stock worth over $296,306. In addition, he makes $479,176 as Chief Financial & Bus. Officer at Nkarta.
Sign up
Dr D NKTX stock SEC Form 4 insiders trading
Dr has made over 12 trades of the Nkarta stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 526 units of NKTX stock worth $2,551 on 20 June 2023.
The largest trade he's ever made was exercising 7,500 units of Nkarta stock on 15 August 2022 worth over $29,175. On average, Dr trades about 2,807 units every 52 days since 2020. As of 20 June 2023 he still owns at least 85,776 units of Nkarta stock.
You can see the complete history of Dr Mahmood stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Nadir Mahmood Ph.D. biography
Dr. Nadir Mahmood Ph.D. is the Chief Financial & Bus. Officer at Nkarta.
What is the salary of Dr D?
As the Chief Financial & Bus. Officer of Nkarta, the total compensation of Dr D at Nkarta is $479,176. There are 1 executives at Nkarta getting paid more, with Paul J. Hastings having the highest compensation of $820,101.
How old is Dr D?
Dr D is 42, he's been the Chief Financial & Bus. Officer of Nkarta since . There are 5 older and no younger executives at Nkarta. The oldest executive at Nkarta, Inc. is Paul J. Hastings, 61, who is the CEO, Pres & Director.
What's Dr D's mailing address?
Nadir's mailing address filed with the SEC is C/O NKARTA, INC., 1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Nkarta
Over the last 4 years, insiders at Nkarta have traded over $2,620,353 worth of Nkarta stock and bought 14,255,554 units worth $205,999,973 . The most active insiders traders include Plc Gsk, Ali Behbahani и Holdings A/S Novo. On average, Nkarta executives and independent directors trade stock every 24 days with the average trade being worth of $1,501,195. The most recent stock trade was executed by Alicia J. Hager on 16 July 2024, trading 3,396 units of NKTX stock currently worth $27,168.
What does Nkarta do?
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
What does Nkarta's logo look like?
Complete history of Dr Mahmood stock trades at Nkarta
Nkarta executives and stock owners
Nkarta executives and other stock owners filed with the SEC include:
-
Paul J. Hastings,
CEO, Pres & Director -
Dr. Nadir Mahmood Ph.D.,
Chief Financial & Bus. Officer -
Dr. Alicia J. Hager,
Chief Legal Officer & Corp. Sec. -
Dr. Kanya Rajangam,
Chief Medical Officer -
Greg Mann,
VP of Public Affairs and Investor Relations -
Dr. James Trager Ph.D., Ph.D.,
Chief Scientific Officer -
Dr. Ralph Brandenberger Ph.D.,
Sr. VP of Technical Operations -
Zachary Scheiner,
-
Leone D Patterson,
-
David Shook,
See Remarks -
George Vratsanos,
-
Michael Dybbs,
-
Ali Behbahani,
-
Nadir Mahmood,
President -
Laura Shawver,
Director -
Kanya Rajangam,
Chief Medical Officer -
Fouad Oscar Azzam,
Director -
Matthew Plunkett,
Chief Financial Officer -
James Trager,
Chief Scientific Officer -
James E Deerfield Mgmt Iv, ...,
-
Capital Management, L.P.Ra ...,
-
Capital Management, L.P.Kol...,
-
Holdings A/S Novo,
10% owner -
Simeon George,
-
Plc Gsk,
Director -
Angela Thedinga,
-
Ralph Brandenberger,
Chief Technical Officer -
Alicia J. Hager,
Chief Legal Officer -
Paul J Hastings,
Chief Executive Officer -
Capital Management, L.P.Ra ...,
-
Tiba Aynechi,
Director -
Alyssa Levin,
See Remarks